Logo Logo Logo Logo Logo
  • Home
  • Our company
    • About us
    • Management
    • Board of directors
    • Investors
  • Our technology
    • Cell Penetrating Alphabodies
    • New Class of Cancer Therapeutics
    • Proof of Concept
  • Pipeline
  • News
  • Careers
  • Partnering
  • Contact us
  • Home
  • Our company
    • About us
    • Management
    • Board of directors
    • Investors
  • Our technology
    • Cell Penetrating Alphabodies
    • New Class of Cancer Therapeutics
    • Proof of Concept
  • Pipeline
  • News
  • Careers
  • Partnering
  • Contact us

28 Jul Complix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmaceutical Co. to Develop Novel Alphabody Therapeutics for Treatment of CNS Diseases

Posted at 10:00h in News
Share

...

Read More

31 Mar Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances

Posted at 08:00h in News
Share
Read More

10 Mar Complix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology Targets

Posted at 15:00h in News
Share
Read More

07 Oct Complix receives €1.2 million VLAIO grant to develop a novel and differentiated class of anti-Covid-19 Alphabody™ therapeutics

Posted at 07:00h in News
Share
Read More

08 May Complix to Present Progress on its Pipeline of Cell Penetrating Alphabodies at BioEquity Europe 2019

Posted at 08:00h in Events
Share
Read More

12 Nov Complix to Present its Cell Penetrating Alphabodies Acting on Important Intracellular Targets at PEGS Europe 2018

Posted at 08:00h in Events
Share
Read More

19 Sep A new technology for targeting proteins inside cells

Posted at 08:00h in News
Share
Read More

09 May Complix to Present Progress on its Pipeline of Cell Penetrating Alphabodies Acting on Intracellular Cancer Targets at BioEquity Europe 2018

Posted at 08:00h in Events
Share
Read More

14 Dec Complix receives €0.5 million grant to further develop its pipeline of proprietary Cell Penetrating Alphabodies™ against intracellular cancer targets

Posted at 09:00h in News
Share
Read More

31 Oct Complix to Present its Cell Penetrating Alphabody™ Platform Acting on Important Intracellular Targets at PEGS Europe 2017

Posted at 09:00h in Events
Share
Read More
  • 1
  • 2
About Complix
Complix is a biopharmaceutical company developing a pipeline of transformative Cell Penetrating Alphabody (CPAB) based biotherapeutics active against cutting-edge and challenging intracellular targets that play a key role in life threatening diseases, including cancer.
Recent news
  • Complix Signs Global Drug Discovery and Development Agreement with Jiangsu Nhwa Pharmaceutical Co. to Develop Novel Alphabody Therapeutics for Treatment of CNS Diseases July 28, 2021
  • Complix and VIB Publish Pioneering Study on Cell-Penetrating Alphabodies in Science Advances March 31, 2021
  • Complix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology Targets March 10, 2021
Complix newsletter
Subscribe to the Complix newsletter & stay up to date with news, events & projects.
Contact us
Technologiepark 94
9052 Zwijnaarde (Ghent)
Belgium
Phone: +32 (0)9 261 69 40
Fax: +32 (0)9 261 69 50
E-Mail: info@complix.com
© 2021 Complix | Terms of use | Privacy policy | Cookie policy